Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rabeprazole · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Rabeprazole Sodium Delayed-Release Tablets 20 mg |
| 2 | ACTIVE_COMPARATOR | Aciphex® Tablets 20 mg |
| Name | Type | Description |
|---|---|---|
| Rabeprazole Sodium Delayed-Release Tablets 20 mg | DRUG | 20mg, single dose fed |
| Aciphex® Tablets 20 mg | DRUG | 20mg, single dose fed |
| Aciphex® Delayed-Release Tablets 20 mg | DRUG | 20mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and non-pregnant, non-lactating female 1. Women of childbearing potential must have negative serum beta-human chorionic gonadotropin (HCG) pregnancy tests performed within 14 days prior to the start of the study and the evening prior ...
Rabeprazole is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is also known as Rabeprazole Sodium Delayed-Release Tablets 20 mg. The clinical trials listed for this asset were conducted in healthy adult volunteers, and the specific therapeutic indication being pursued is not disclosed.
Rabeprazole targets ATP4A and ATP4B. It is classified as an inhibitor of these targets. ATP4A and ATP4B form the gastric proton pump, and inhibiting this pump is the mechanism by which rabeprazole acts as a small molecule therapeutic.
Rabeprazole is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the sponsor of the clinical trials evaluating Rabeprazole Sodium Delayed-Release Tablets 20 mg.
Rabeprazole is in Phase 1 clinical development. It is an investigational asset and is not described as approved. Two Phase 1 trials have been completed, and no trials are currently active.
Rabeprazole has been studied in two completed Phase 1 trials: NCT00649194, a food-effect study comparing Rabeprazole Sodium Delayed-Release Tablets 20 mg with Aciphex tablets 20 mg, and NCT00648349, a fasting study with the same comparison. Both enrolled 72 healthy volunteers in the United States, for a total enrollment of 144.